GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) valuation and DCF model
At $124.40 the price implies revenue of $19.47 billion by year ten, growing 61.0% a year, at a 10% free-cash-flow margin then.
- The price needs
- 61.0% a year for ten years
- $124.40
- today’s price
Base case on its own ten-year record GRAIL, Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$(3.86b) 10 years of cash to equity+$1.59b terminal value+$861.61m net cash=$(1.41b) equity value÷41.82m shares=$(33.75) per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/B | 2.37× | 0.81× | 0.81× | 193% above | 3.42× | 31% below | |
| EV/EBITDA | — | 0.32× | 0.32× | — | 23.44× | — | |
| EV/Sales | 29.76× | 22.49× | 22.49× | 32% above | 5.18× | 475% above |
GRAL trades at 2.37× P/B, against a 10-year average of 0.81× (range 0.12×–2.37×). That is dearer than 100% of the last 4 year-end readings; re-rating to the average implies $42.51 per share.